期刊
THERAPEUTIC ADVANCES IN HEMATOLOGY
卷 4, 期 3, 页码 189-198出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/2040620713480522
关键词
Bcl-2; follicular lymphoma; minimal residual disease; next-generation sequencing; polymerase chain reaction
类别
资金
- Ministero Italiano dell'Universita e della Ricerca (MIUR), Roma, Italy [7.07.02.60 AE01]
- IRCCS Centro di Riferimento Oncologico della Basilicata (CROB), Rionero in Vulture (Potenza), Italy [7.07.08.60 P49]
- Divisione di Ematologia, A. O. S. Maurizio, Bolzano/Bozen, Italy [7.07.08.60 P51, RF-2009-1469205, RF-2010-2307262]
- Fondi di Ricerca Locale, Universia degli Studi di Torino, Torino, Italy
- Fondazione Neoplasie del sangue (FO.NE.SA), Torino, Italy
The identification of patients at high risk of relapse is a critical goal of modern translational research in oncohematology. Minimal residual disease (MRD) detection by polymerase chain reaction-based methods is routinely employed in the management of patients with acute lymphoblastic leukemia. Current knowledge indicates that it is also a useful prognostic tool in several mature lymphoproliferative disorders and particularly in follicular lymphoma (FL). Based on this evidence clinical trials employing MRD-based risk stratification are currently ongoing in FL. In this review the 'state of the art' of MRD evaluation in FL is discussed. A short description of technical issues and recent methodological advances is provided. Then, the bulk of the review focuses on critical take-home messages for clinicians working in the field. Finally, we discuss future perspectives of MRD detection and more generally outcome prediction in FL.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据